Determination of the Designer Drugs 3,4-Methylenedioxymethamphetamine, 3,4-Methylenedioxyethylamphetamine, and 3,4-Methylenedioxyamphetamine with HPLC and Fluorescence Detection in Whole Blood, Serum, Vitreous Humor, and Urine
Karine M. Clauwaert, Jan F. van Bocxlaer, Els A. de Letter, Serge van Calenbergh, Willy E. Lambert, A.p. de Leenheer
Clinical Chemistry December 1, 2000 DOI: 10.1093/clinchem/46.12.1968 via OpenAlex
Summary
AI-generated from the abstractA method using high-performance liquid chromatography with fluorescence detection, confirmed by liquid chromatography-tandem mass spectrometry, accurately measures the designer drugs MDMA, MDEA, and their metabolite MDA in whole blood, serum, vitreous humor, and urine. The method is linear from 2 to 1000 μg/L for blood, serum, and vitreous humor, and from 0.1 to 5 mg/L for urine, with detection limits as low as 0.8 μg/L. Extraction recoveries exceed 70%, and imprecision ranges from 2.5% to 19%. In a rabbit thanatochemical distribution study, serum MDMA concentrations ranged from 5.3 to 685 μg/L, and whole blood MDMA from 19.7 to 710 μg/L. For routine toxicology urine samples, MDMA concentrations reached up to 157 mg/L.
Study at a glance
| Characteristics | Method validation and thanatochemical distribution study Peer reviewed |
|---|---|
| Population | Rabbits (thanatochemical distribution study) and human urine samples (routine toxicology) |
| Keywords | Detection limit Urine Elution High-performance liquid chromatography Whole blood |
| Citations | 68 |
| Key finding | The HPLC method is sensitive and specific for quantifying MDMA, MDEA, and MDA in whole blood, serum, vitreous humor, and urine, with linear ranges, low detection limits, and good correlation with LC-MS/MS results. |
Abstract
Abstract Background: The popular designer drugs 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyethylamphetamine (MDEA) can be determined in serum, whole blood, and urine, but also in vitreous humor. The latter matrix is interesting when dealing with decomposed bodies in a toxicological setting. Methods: After extraction, chromatographic separation was achieved on a narrow-bore C18 column by gradient elution with fluorometric detection; results were confirmed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results: The method was linear over the range of 2–1000 μg/L for whole blood, serum, and vitreous humor, and 0.1–5 mg/L for urine. Extraction recoveries were >70%, imprecision (CV) was 2.5–19%, and analytical recoveries were 95.5–104.4%. The limit of detection (LOD) and the limit of quantification (LOQ) were 0.8 and 2 μg/L, respectively, for whole blood, serum, and vitreous humor, and 2.5 μg/L and 0.1 mg/L, respectively, for urine. Excellent correlations between the quantitative LC-fluorescence and LC-MS/MS results were obtained. We found the following concentrations in a thanatochemical distribution study in rabbits: in serum, 5.3–685 μg/L for MDMA and from the LOQ to 14.5 μg/L for 3,4-methylenedioxyamphetamine (MDA); in whole blood, 19.7–710 μg/L for MDMA and from the LOQ to 17.8 μg/L for MDA; in vitreous humor, 12.1–97.8 μg/L for MDMA and from the LOQ to 3.86 μg/L for MDA. In routine toxicological urine samples, concentrations ranged from LOQ to 14.62 mg/L for MDA, from LOQ to 157 mg/L for MDMA, and from LOQ to 32.54 mg/L for MDEA. Conclusions: The HPLC method described is sensitive, specific, and suitable for the determination of MDMA, MDEA, and MDA in whole blood, serum, vitreous humor, and urine.